DESTINY-Breast04: Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Source: View publication →
In patients with previously treated, HER2-low advanced breast cancer, trastuzumab deruxtecan significantly improved both progression-free and overall survival compared to standard chemotherapy, establishing a new therapeutic paradigm.
Key Findings
Study Design
Study Limitations
Clinical Significance
DESTINY-Breast04 is a paradigm-shifting trial that fundamentally redefined breast cancer classification and treatment. By establishing 'HER2-low' (IHC 1+ or 2+/ISH-) as a distinct, actionable biomarker, it extended the use of highly effective targeted antibody-drug conjugates to approximately 50% of all breast cancer patients who were previously treated as HER2-negative, doubling progression-free survival and significantly prolonging overall survival compared to traditional cytotoxic chemotherapy.
Historical Context
Historically, HER2 status in breast cancer was viewed as a binary biomarker. Only patients with HER2-overexpressing or amplified tumors (IHC 3+ or IHC 2+/ISH+) benefited from traditional anti-HER2 therapies like trastuzumab and T-DM1. Tumors with low HER2 expression were categorized as HER2-negative and treated with standard endocrine therapy or chemotherapy. Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate with a highly membrane-permeable payload, demonstrated a unique 'bystander effect' capable of eliminating adjacent tumor cells with low or no HER2 expression. DESTINY-Breast04 capitalized on this pharmacological breakthrough to completely alter the landscape of metastatic breast cancer.
Guided Discussion
High-yield insights from every perspective
How does the unique mechanism of action of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) allow it to be highly effective in HER2-low breast cancer, whereas traditional HER2-targeted monoclonal antibodies like trastuzumab are ineffective?
Key Response
T-DXd utilizes a 'bystander effect'. While traditional trastuzumab requires high levels of HER2 expression to inhibit downstream signaling, T-DXd uses HER2 primarily as a homing beacon. Once bound to HER2-low cells, it is internalized, and a cleavable linker releases a highly potent topoisomerase I inhibitor (deruxtecan). Because this payload is membrane-permeable, it diffuses into and destroys neighboring tumor cells regardless of their individual HER2 expression, overcoming the heterogeneous HER2 expression typical of HER2-low tumors.
A patient with HR-positive, HER2-low metastatic breast cancer progresses on endocrine therapy and is started on trastuzumab deruxtecan. During a routine follow-up, she reports a mild, new-onset dry cough but is otherwise asymptomatic. What is the most critical differential diagnosis to consider, and what is the immediate management?
Key Response
The most critical, potentially fatal adverse event associated with T-DXd is interstitial lung disease (ILD) or pneumonitis. Even for Grade 1 (asymptomatic, radiologic findings only) or mild symptomatic disease, the management requires immediate interruption of T-DXd, a high-resolution CT scan, and initiation of systemic corticosteroids. T-DXd must be permanently discontinued for any ILD that is Grade 2 or higher.
Given the therapeutic success of T-DXd in DESTINY-Breast04, how does the new clinical relevance of the 'HER2-low' classification complicate traditional pathology workflows, and what are the limitations of current immunohistochemistry (IHC) scoring in distinguishing IHC 0 from IHC 1+?
Key Response
Historically, the distinction between IHC 0 and 1+ was clinically irrelevant, as both were treated as 'HER2-negative'. Consequently, inter-observer agreement among pathologists at the lower end of the IHC spectrum is notoriously poor. The DESTINY-Breast04 trial makes this distinction a critical gatekeeper for a highly efficacious therapy, highlighting the urgent need for more quantitative and reproducible HER2 assays (e.g., quantitative image analysis or RT-PCR) to accurately identify true IHC 0 versus IHC 1+ and to explore the emerging 'HER2-ultra-low' category.
With DESTINY-Breast04 blurring the traditional binary lines of HR-positive/HER2-negative and Triple-Negative Breast Cancer (TNBC), how should we conceptualize sequencing algorithms for patients who are clinically TNBC but immunohistochemically HER2-low, particularly regarding the use of other antibody-drug conjugates?
Key Response
For a patient traditionally classified as TNBC who is HER2-low, T-DXd is now a highly effective option alongside the Trop-2 targeted ADC sacituzumab govitecan. The attending must weigh sequencing ADCs (e.g., T-DXd followed by sacituzumab or vice versa). A major clinical dilemma is the potential for cross-resistance, as both ADCs utilize a topoisomerase I inhibitor payload. Careful consideration of prior toxicities, disease tempo, and emerging real-world data on ADC-after-ADC sequencing is required.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
DESTINY-Breast04 included both HR-positive and HR-negative (TNBC) cohorts, but the TNBC cohort comprised only about 11% of the total study population. How does the hierarchical statistical testing structure and the powering of this trial influence the formal interpretation of the overall survival (OS) benefit specifically within the exploratory HR-negative subgroup?
Key Response
The trial was primarily powered to detect differences in the HR-positive cohort. The hierarchical testing gatekeeping strategy evaluated PFS in HR+, then PFS in all patients, then OS in HR+, and finally OS in all patients. Because the HR-negative group was essentially an exploratory cohort with small sample size, formal statistical significance for OS cannot be independently claimed for this subgroup alone, despite the impressive hazard ratios. Researchers must critique the generalizability of these TNBC findings and design appropriately powered dedicated trials for this subpopulation.
The control arm in DESTINY-Breast04 utilized 'Treatment of Physician's Choice' (TPC) chemotherapy. As a critical reviewer, how might the selection of specific agents within TPC, and the availability of post-progression therapies, introduce bias or threaten the internal validity of the reported overall survival benefit?
Key Response
A seasoned reviewer would flag the lack of a standardized control arm. If the TPC agents (capecitabine, eribulin, gemcitabine, paclitaxel, nab-paclitaxel) selected by investigators were not uniformly optimized or if patients in the control arm had limited access to robust post-progression therapies compared to real-world standards, the control arm might underperform. The reviewer must examine the performance of the TPC arm against historical benchmarks to ensure the OS delta is driven by T-DXd's exceptional efficacy rather than control arm underperformance.
Based on the DESTINY-Breast04 results, how should NCCN and ASCO guidelines formally update the treatment algorithms for HER2-negative metastatic breast cancer, and what specific level of evidence supports the prioritization of trastuzumab deruxtecan over sequential single-agent chemotherapy in the second-line setting?
Key Response
DESTINY-Breast04 provides Category 1 (NCCN) / High-Quality (ASCO) evidence to establish a formal 'HER2-low' biomarker subset within breast cancer guidelines. Current guidelines must be updated to explicitly recommend T-DXd as the preferred targeted therapy for HER2-low (IHC 1+ or 2+/ISH-negative) patients who have received at least one prior line of chemotherapy in the metastatic setting, or who progressed within 6 months of adjuvant chemotherapy, effectively superseding traditional sequential single-agent chemotherapies in this space.
Clinical Landscape
Noteworthy Related Trials
EMILIA Trial
Tested
Trastuzumab emtansine (T-DM1)
Population
HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane
Comparator
Capecitabine plus lapatinib
Endpoint
Progression-free survival (PFS) and overall survival (OS)
DESTINY-Breast03
Tested
Trastuzumab deruxtecan (T-DXd)
Population
HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane
Comparator
Trastuzumab emtansine (T-DM1)
Endpoint
Progression-free survival (PFS)
TROPiCS-02
Tested
Sacituzumab govitecan
Population
HR-positive, HER2-negative metastatic breast cancer previously treated with endocrine therapy and chemotherapy
Comparator
Treatment of physicians choice (chemotherapy)
Endpoint
Progression-free survival (PFS)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis